No Data
No Data
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40
Cartesian Therapeutics' Descartes-08 Secures FDA Rare Pediatric Disease Designation to Treat Juvenile Dermatomyositis
Express News | Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
Cartesian Therapeutics Announces New Employment Inducement Grant
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $45
Buy Rating on Cartesian Therapeutics: Advancing Cell Therapy With Innovative MRNA-Engineered CAR-T Treatments